48.62
-2.02 (-3.99%)
| Penutupan Terdahulu | 50.64 |
| Buka | 50.80 |
| Jumlah Dagangan | 1,031,220 |
| Purata Dagangan (3B) | 1,534,461 |
| Modal Pasaran | 3,451,382,528 |
| Harga / Buku (P/B) | 8.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| EPS Cair (TTM) | -3.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.18% |
| Nisbah Semasa (MRQ) | 27.68 |
| Aliran Tunai Operasi (OCF TTM) | -155.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -97.14 M |
| Pulangan Atas Aset (ROA TTM) | -23.46% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vera Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.13 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.97% |
| % Dimiliki oleh Institusi | 112.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 97.00 (Evercore ISI Group, 99.51%) | Beli |
| Median | 90.00 (85.11%) | |
| Rendah | 33.00 (Wedbush, -32.13%) | Pegang |
| Purata | 78.57 (61.60%) | |
| Jumlah | 6 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 45.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 19 Dec 2025 | 66.00 (35.75%) | Beli | 51.22 |
| Goldman Sachs | 19 Dec 2025 | 95.00 (95.39%) | Beli | 51.22 |
| JP Morgan | 19 Dec 2025 | 96.00 (97.45%) | Beli | 51.22 |
| 07 Nov 2025 | 52.00 (6.95%) | Beli | 24.19 | |
| Wedbush | 11 Dec 2025 | 33.00 (-32.13%) | Pegang | 46.02 |
| Evercore ISI Group | 08 Dec 2025 | 97.00 (99.51%) | Beli | 45.03 |
| TD Cowen | 05 Dec 2025 | 73.00 (50.14%) | Beli | 44.90 |
| HC Wainwright & Co. | 10 Nov 2025 | 90.00 (85.11%) | Beli | 27.75 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |